The Patent Finder

First Tracks Biotherapeutics, Inc.

12 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Feb 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 15, 2027
    The maintenance fee for Humanized Antibodies Directed Against Complement Protein C5 (US 9,133,269) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 1 fee due Aug 16, 2027
    The maintenance fee for Methods of Generating Libraries and Uses Thereof (US 9,260,533) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
  • 1 fee due Nov 3, 2027
    The maintenance fee for Antibodies Directed Against IL-17 (US 9,328,166) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,685,897Methods of Generating Libraries and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,260,533Methods of Generating Libraries and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,637,556Methods of Generating Libraries and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 8,603,950Methods of Generating Libraries and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,328,166Antibodies Directed Against IL-17
In force
 · High confidence
In forceHigh confidence
US 8,926,978Antibodies Directed Against Nerve Growth Factor (NGF)
In force
 · High confidence
In forceHigh confidence
US 9,951,126Antibodies Directed Against Nerve Growth Factor (NGF)
In force
 · High confidence
In forceHigh confidence
US 9,133,269Humanized Antibodies Directed Against Complement Protein C5
In force
 · High confidence
In forceHigh confidence
US 10,059,764Antibodies Directed Against INTERLEUKIN-33 (IL-33) and Methods of Making and Using
In force
 · High confidence
In forceHigh confidence
US 10,836,820Method of Treating Inflammatory Disorder with Antibodies Directed Against INTERLEUKIN-33 (IL-33)
In force
 · High confidence
In forceHigh confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited